Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
TAVR
MedTech
Boston Scientific puts $1.5B into MiRus, option to buy its TAVR
Boston Scientific is making a major investment play into a private medtech with an option to snap up exclusive rights to its TAVR system.
Ben Adams
May 18, 2026 8:31am
JenaValve secures FDA's 1st approval in aortic regurgitation
Mar 18, 2026 10:05am
FTC outlines antitrust case against Edwards' JenaValve deal
Nov 25, 2025 3:10pm
At ESC 2025, researchers call for earlier, simpler TAVR
Aug 29, 2025 1:00pm
FTC aims to stop Edwards' acquisition of JenaValve
Aug 7, 2025 11:33am
Abbott eyes structural heart gains after Boston Scientific exit
Jul 17, 2025 1:00pm
